Added to YB: 2024-11-07
Pitch date: 2024-09-21
INMB [bullish]
INmune Bio, Inc.
+73.31%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
Market Cap
$187.6M
Pitch Price
$5.32
Price Target
N/A
Dividend
N/A
Sector
Biotechnology
Category
growth
Show full summary:
INmune Bio, Inc. - $INMB
INMB: XPro a-TNF targets AD, crossing BBB w/o immune suppression. Ph1 showed disease reversal in some patients. Ph2 results Q2 2025. Potential for multiple indications (MS, DMD, TRD). Mgt owns 1/3. $116M mkt cap. High risk/reward: $0 or $1000s/share. Ph2 success could be blockbuster.
Read full article (9 min)